Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data

Figures & data

Figure 1 Flow chart for patient’s selection.

Figure 2 International index of erectile function – erectile function domain (IIEF-EF) in 77 hypogonadal men with a CVD history receiving continuous treatment with testosterone undecanoate. Data are shown as mean. *p<0.0001 vs baseline. #p<0.0001 vs previous year.

Figure 3 Anthropometric parameters in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.

Notes: (A) Body weight (kg), (B) weight loss (%), (C) waist circumference (cm), and (D) BMI (kg/m²). Data are shown as mean. *p<0.0001 vs baseline. #p<0.0001 vs previousyear.

Abbreviation: BMI, body mass index.

Figure 4 HbA_1c (%) in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.

Notes: Data are shown as mean. *p<0.0001 vs baseline. #p<0.0001 vs previousyear.

Abbreviation: HbA_1c, glycated hemoglobin.

Figure 5 (A) Systolic and (B) diastolic blood pressure (mmHg) in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy. (C) Pulse pressure in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.

Notes: (A) Systolic blood pressure and (B) diastolic blood pressure. Data are shown as mean. *p<0.0001 vs baseline. #p<0.0001 vs previousyear.

Abbreviation: NS, nonsignificant.

Figure 6 Serum lipids in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy (A) total cholesterol, (B) LDL-cholesterol, (C) triglycerides and (D) HDL-cholesterol. Note: Data are shown as mean. *p<0.0001 vs baseline. #p<0.0001 vs previous year.

Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; NS, nonsignificant.